logo

For the Inventor, By the Inventor

Brookline, MA, United States of America

Matthew Christopher

This inventor holds 18 USPTO granted patents and 10 EPO patents, primarily in Kinase Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc.. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Christopher. Retrieved from https://idiyas.com/inventor/matthew-christopher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18

% Patents Active = 100.0

 

Average Co-Inventor Count = 14.0

ph-index = 2

Forward Citations = 31(Granted Patents)


Location History:

  • Wallingford, CT (US) (2013)
  • Brookline, MA (US) (2013 - 2022)

Company Filing History:

goldMedal18 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal5 out of 40 
 
Merck Canada Inc.
 patents
where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...
Loading Chart...
Areas of Expertise:
Kinase Inhibitors
Syk Inhibitors
HDM2 Inhibitors
Janus Kinase
Purine Derivatives
Triazole Derivatives
Pyrrolopyrimidines
Imidazolyl Analogs
Cyanomethylpyrazole
Substituted Pyridine
Substituted Diazine
Alzheimer's Treatment
18 patents (USPTO):Explore Patents
1. 11230547 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2022-01-25),
2. 10544147 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2020-01-28),
3. 9938281 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-04-10),
4. 9730940 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2017-08-15),
5. 9682978 - 2,6,7 substituted purines as HDM2 inhibitors (2017-06-20),
6. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),
7. 9540377 - 2,6,7,8 substituted purines as HDM2 inhibitors (2017-01-10),
8. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),
9. 9416111 - Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors (2016-08-16),
10. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),
11. 9353066 - Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors (2016-05-31),
12. 9328099 - Cyanomethylpyrazole carboxamides as janus kinase inhibitors (2016-05-03),
13. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),
14. 8993756 - Pyrrolopyrimidines as janus kinase inhibitors (2015-03-31),
15. 8962611 - Substituted imidazopyridines as HDM2 inhibitors (2015-02-24),

Title: The Innovative Mind of Matthew Christopher

Introduction

Matthew Christopher, based in Brookline, MA, is a prominent inventor recognized for his significant contributions to medical research and development. With an impressive portfolio of 18 patents, he has made remarkable strides in the field of pharmaceutical innovation, particularly in developing treatments for serious health conditions.

Latest Patents

Among Matthew's latest inventions are purine inhibitors of human phosphatidylinositol 3-kinase delta. These patented compounds, referred to as formulas Ia and Ib, serve as PI3K-delta inhibitors and are instrumental in treating diseases mediated by this pathway, such as inflammation, asthma, chronic obstructive pulmonary disease (COPD), and cancer. His expertise is reflected in his recent patents, which collectively address critical healthcare challenges and offer promising therapeutic options.

Career Highlights

Matthew's career spans notable positions at renowned biopharmaceutical companies, specifically Merck Sharp & Dohme Corporation and Merck Canada Inc. Throughout his tenure, he has been at the forefront of innovative research, driving projects that intersect biotechnology and pharmacology. His work has earned him recognition in the scientific community, solidifying his reputation as an inventive force.

Collaborations

In the course of his career, Matthew has collaborated with respected professionals in the industry, including Michael D. Altman and Michael Hale Reutershan. These partnerships have not only facilitated the advancement of his inventions but also contributed to a collaborative spirit in the research environment, leading to greater innovation and discovery.

Conclusion

Matthew Christopher exemplifies the essence of innovation in the pharmaceutical realm. His patents demonstrate a commitment to addressing significant health issues through scientific research and technological advancements. As a dedicated inventor, Matthew continues to pave the way for new treatments that have the potential to change lives for the better.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…